Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

857 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High accuracy of recombinant fusion protein early secretory antigenic target protein 6-culture filtrate protein 10 skin test for the detection of tuberculosis infection: a phase III, multi-centered, double-blind, hospital-based, randomized controlled trial.
Xia L, Xu M, Li F, Li T, Yang H, Wang W, Wu Q, Li Y, Chen X, Ou Q, Chu N, Pan H, Deng Q, Mei X, Lowrie DB, Liu X, Wang G, Lu S. Xia L, et al. Among authors: chu n. Int J Infect Dis. 2023 Jan;126:98-103. doi: 10.1016/j.ijid.2022.11.014. Epub 2022 Nov 15. Int J Infect Dis. 2023. PMID: 36400376 Free article. Clinical Trial.
Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China.
Wang Q, Pang Y, Jing W, Liu Y, Wang N, Yin H, Zhang Q, Ye Z, Zhu M, Li F, Liu P, Wu T, Chen W, Wu W, Qin Z, Qiu C, Deng Q, Xu T, Wang J, Guo R, Du Y, Wang J, Huang H, Chen X, Chu N. Wang Q, et al. Among authors: chu n. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02149-17. doi: 10.1128/AAC.02149-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29378718 Free PMC article. Clinical Trial.
Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial.
Duan H, Chen X, Li Z, Pang Y, Jing W, Liu P, Wu T, Cai C, Shi J, Qin Z, Yin H, Qiu C, Li C, Xia Y, Chen W, Ye Z, Li Z, Chen G, Wang S, Liu Y, Chu L, Zhu M, Xu T, Wang Q, Wang J, Du Y, Wang J, Chu N, Xu S. Duan H, et al. Among authors: chu l, chu n. Clin Microbiol Infect. 2019 Feb;25(2):190-195. doi: 10.1016/j.cmi.2018.07.012. Epub 2018 Jul 21. Clin Microbiol Infect. 2019. PMID: 30036672 Free article. Clinical Trial.
Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen.
Zhang SY, Fu JY, Guo XY, Wu DZ, Zhang T, Li C, Qiu L, Shao CR, Xiao HP, Chu NH, Deng QY, Zhang X, Yan XF, Wang ZL, Zhang ZJ, Jiang X, Zheng YJ, Zheng PY, Zhang HY, Lu ZH. Zhang SY, et al. Infect Dis Poverty. 2020 May 7;9(1):50. doi: 10.1186/s40249-020-00660-z. Infect Dis Poverty. 2020. PMID: 32381098 Free PMC article. Clinical Trial.
Adjunctive interleukin-2 for the treatment of drug-susceptible tuberculosis: a randomized control trial in China.
Nie W, Wang J, Zeng J, Wang Q, Du Y, Tan Q, Xie W, Deng Q, Deng G, Li X, Li Z, Zhao J, Pang J, Luan K, Chu L, Duan H, Zhang C, Ji Q, Chen X, Chen J, Wang N, Chen Y, Qiu C, Deng A, Ren P, Liu Y, Li C, Cao S, Liu H, Yan H, Chu N. Nie W, et al. Among authors: chu l, chu n. Infection. 2022 Apr;50(2):413-421. doi: 10.1007/s15010-021-01698-3. Epub 2021 Sep 25. Infection. 2022. PMID: 34562262 Clinical Trial.
Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China.
Wang J, Pang Y, Jing W, Chen W, Guo R, Han X, Wu L, Yang G, Yang K, Chen C, Jiang L, Cai C, Dou Z, Diao L, Pan H, Wang J, Du F, Xu T, Wang L, Li R, Chu N. Wang J, et al. Among authors: chu n. Infect Drug Resist. 2019 Apr 3;12:763-770. doi: 10.2147/IDR.S194484. eCollection 2019. Infect Drug Resist. 2019. PMID: 31040707 Free PMC article.
857 results